Clinical Trial Update: Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial evaluating the combination of fludarabine, cyclophosphamide, doxorubicin, and rituximab for post-transplant lymphoproliferative disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-transplant Lymphoproliferative Disease

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• Fludarabine (Fludarabine)
• Rituximab (rituximab)

Snippet

Sponsor: A.O. Ospedale Papa Giovanni XXIII | Conditions: Post-transplant Lymphoproliferative Disease (PTLD), Non Burkitt | Phase 4 | Status: COMPLETED